Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265976 | 0.76 | DHODH (0.57) | MAPTPOLBSMN1; SMN2TGFBR1TAS2R14 | |
| SCHEMBL14322617 | 0.74 | NPC1 (0.33) | MAPTSMN1; SMN2KDM4ETDP1LMNA | |
| SCHEMBL10697169 | 0.68 | TGFBR1 (0.58) | MAPTPOLBSMN1; SMN2TGFBR1TAS2R14 | |
| SCHEMBL2550512 | 0.66 | KDM4E (0.37) | MAPTKDM4ETDP1MEN1KMT2A | |
| SCHEMBL10407098 | 0.66 | LMNA (0.47) | MAPTPOLBSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL19436706 | 0.66 | KDM4E (0.66) | MAPTPOLBSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL10407097 | 0.66 | LMNA (0.47) | MAPTPOLBSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL2731383 | 0.65 | PTGS1 (0.44) | TGFBR1KDM4EASPHTDP1HDAC4 | |
| SCHEMBL23534429 | 0.64 | RXFP1 (0.49) | MAPTSMN1; SMN2KDM4ELMNAHDAC4 | |
| SCHEMBL23883092 | 0.63 | CA12 (0.41) | MAPTKDM4ELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263592-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263592-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR1A, HTR2A, HTR2B | MAPT 1462/4885POLB 4186/4885SMN1; SMN2 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.